other material
confidence high
sentiment positive
materiality 0.65
Aadi Bioscience reports 26% ORR in TSC1 arm, 11% in TSC2 arm from PRECISION1 interim analysis
Whitehawk Therapeutics, Inc.
- TSC1 arm (n=22): 26% ORR (5 PRs, 4 confirmed), 42% clinical benefit rate, median 3 prior therapies.
- TSC2 arm (n=18): 11% ORR (2 PRs, 1 confirmed), 28% clinical benefit rate, 50% had ≥5 prior lines.
- No new safety signals; one grade 2 pneumonitis resolved; safety consistent with mTOR class.
- 80 patients now enrolled; two-thirds interim analysis expected 3Q 2024; trial completion by end 2024.